# A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)

Source: https://onco.cc/trials/nct07060807/  
OnCo record `nct07060807` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Patritumab deruxtecan, Capecitabine, Doxorubicin and Trastuzumab deruxtecan in advanced solid tumours, run by Merck Sharp & Dohme LLC, now recruiting.

## Summary

A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016) is a phase 3 interventional study registered as NCT07060807 by Merck Sharp & Dohme LLC, with 1000 participants planned, started 2025-07-21 and due to reach its primary completion in 2033-07-14. Interventions recorded: Patritumab deruxtecan, Paclitaxel, Nab-paclitaxel, Capecitabine, Liposomal doxorubicin and Trastuzumab deruxtecan.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07060807
- Phase: 3
- Setting: An Open-label, Randomized, Phase 3 Study to Evaluate Patritumab Deruxtecan Monotherapy Versus Treatment of Physician's Choice in Hormone Receptor-positive, HER2-negative Unresectable Locally Advanced or Metastatic Breast Cancer (HERTHENA-Breast04).
- Sponsor: Merck Sharp & Dohme LLC
- Enrolled: 1000

## Sources

- ClinicalTrials.gov NCT07060807: https://clinicaltrials.gov/study/NCT07060807

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [Capecitabine](https://onco.cc/drugs/capecitabine/), [Doxorubicin](https://onco.cc/drugs/doxorubicin/), [Patritumab deruxtecan](https://onco.cc/drugs/patritumab-deruxtecan/), [Trastuzumab deruxtecan](https://onco.cc/drugs/trastuzumab-deruxtecan/)
- companies: [Daiichi Sankyo](https://onco.cc/companies/daiichi-sankyo/), [Merck & Co. (MSD)](https://onco.cc/companies/merck/)

---
JSON: https://onco.cc/api/v1/entities/nct07060807.json